Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Lung Cancer ◽  
2019 ◽  
Vol 127 ◽  
pp. 84-89 ◽  
Author(s):  
Xiaohua Gu ◽  
Qiang Zhang ◽  
Yun-Bo Chu ◽  
Yi-Yang Zhao ◽  
Yan-Jun Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line

scholarly journals Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer

JAMA Oncology ◽  
2018 ◽  
Vol 4 (8) ◽  
pp. 1080 ◽  
Author(s):  
Pedro N. Aguiar ◽  
Benjamin Haaland ◽  
Wungki Park ◽  
Pui San Tan ◽  
Auro del Giglio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cost Effectiveness ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document